Arcus Biosciences (RCUS) Q3 2026 earnings — TrendMatrix coverage

Adjusted EPS

-$1.00

Estimate

-$0.89

Surprise

-12.0%

Revenue (period 2026-09-30)

$3.0M

Score today

4.6/10

Revenue source: xbrl.

Arcus Biosciences (RCUS) reported a wider loss than forecast — adjusted EPS of -$1.00 against the -$0.89 estimate (a 12.0% shortfall).

• Analyst Coverage Updates for Arcus Biosciences — fiscal.ai, 2026-11-05
• Leerink Partners Maintains Outperform on Arcus Biosciences, Raises Price Target to $49 — benzinga, 2026-11-05
• Truist Securities Maintains Buy on Arcus Biosciences, Lowers Price Target to $40 — benzinga, 2026-11-05

TrendMatrix currently rates RCUS Sell at 4.6/10; no pre/post engine snapshot brackets this report.

2 of the last 4 quarters beat the estimate; this quarter's -12.0% surprise compares with a -1.6% four-quarter average. Next scheduled report: 2027-02-24.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$18.15

Price target

$35.67

Stop

$16.91

Upside to target

+96.5%

Reward-to-risk

6.4:1

Model outputs from TrendMatrix’s engine as of 2026-11-06 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$2.25B

P/E (fwd)

-5.7

52-week range

$17.43–$31.73

Off 52-week high

42.8%

RSI (14)

35

Volume vs avg

0.06×

Score today

4.6/10